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Background: Mitral Valve Repair (MVRP) has been shown to be significantly superior to Mitral Valve Replacement
(MVR). Since the majority of repairs involve the Posterior Mitral Leaflet (PML) and not the Anterior Mitral Leaflet
(AML), the monocuspidalisation of the Mitral Valve (MV) can be achieved with a bio-posterior leaflet that imitates a
closed PML. This approach may have the benefit of restoring the competence of the MV without reducing its
effective orifice area.
Methods: We have used a new concept and device, the MitroFixTM, to correct MV regurgitation due to pathology
of the PML. The device comes with functional sizers both of which have identical shape and size. This allows the
surgeon to pre-test the success of the restoration. From December 2006 to October 2011, 51 MitroFixTM devices
were implanted at three institutions.
Results: The mean age of the patients (32 males and 19 females) was 67.7 years. 37 of them were in NYHA class III
or IV and all patients suffered from severe mitral valve regurgitation (MR). 31 patients underwent combined surgery.
Successful implantation of the MitroFix™ device was performed in 51/53 patients.Mean cross-clamp time was 63.6
min (range: 29-118 min). Six patients had additional reconstructive procedures of the AML (chordae transfer,
neo-chordae, triangular resection). At discharge, 33 patients showed no MR in the TTE and 17 patients exhibited
trivial (I) or moderate (II) MR. The mean gradient was 4.0 mmHg and mean EOA was 2.52cm^2 (range: 1.5-4.0cm2).
All patients were classified as being in NYHA class I or II.
Conclusion: The MitroFixTM Mitral Valve Restoration Device is a new concept that offers an effective treatment of
MR. The restoration of the mitral valve with the MitroFix™ device offers the advantage of preserving the AML and
providing good coaptation with a prosthetic PML. Importantly, this preliminary evaluation indicates a mean
effective orifice area ( EOA ) of 2.5cm2 in MV receiving a MitroFix™ device, witch is higher than EOA resulting from
MVR or MVRP. The present study has also shown that severe regurgitation due to ischemic/rheumatic MR,
endocarditis and complex prolapse of the PML are clear candidates for correction with the MitroFix™. Larger studies
and a longer follow up period are needed to validate these promising results.Background
Mitral valve repair (MVRP) is the preferred treatment
for patients with mitral valve regurgitation (MR) with
important advantages over mitral valve replacement
(MVR), including: (I) reduced operative mortality, (II)
improved long-term survival, (III) better preservation of
left ventricular function and hemodynamics, and (IV)
greater freedom from endocarditis, thromboembolism,
and anticoagulant- related hemorrhages [1].* Correspondence: karl.golczyk@klinikum-augsburg.de
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reproduction in any medium, provided the orDespite these well-established benefits, however, less
than 65% of diseased mitral valves are repaired [2],
largely owed to the many surgical/technical challenges
associated to this procedure, and also to a variety of
clinical scenarios which make the patient ill-suited for
conventional repair [3]. The rate of repair could vary
from 10% to 90% depending on the type of mitral valve
pathology [4]. Replacement is a very quick and reprodu-
cible procedure with predictable result, whereas repair is
time consuming, requires a considerable experience of
the surgeon and it is accompanied by a learning curve.
Even among skilled surgeons, the feasibility and the
outcome of MVRP can be highly variable, mainly due totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tween 2% and 5% and even higher have been reported at
11 years follow-up [5,6], while the rate of failures during
surgery and during the early postoperative period
remains unknown.
Shortcomings of MV annuloplasty
One of the basic techniques of MVRP is the use of an
annuloplasty ring to stop or reverse annular dilatation
[7]. The annuloplasty ring increases coaptation by de-
creasing the anterior-posterior dimension of the mitral
annulus. This transformed the MV into a single leaflet
mechanism (monocuspidalisation) with a frozen poste-
rior leaflet (PML) serving as a buttress for the closing
even in non-diseased valves [8]. The result of this ap-
proach is a reduction of the EOA.
Potential benefit and conditions that could be suitable
for the restoration of the MV competence with the
MitroFixTM device
The feasibility of MVRP depends on the pathology of
the regurgitation. In general more than 90% of the MV
[4] with degenerative disease and isolated prolapse of
the posterior leaflet (Type II) can be repaired using con-
ventional techniques with good long-term results in
terms of freedom from reoperation, bleeding or
thromboembolic events [9]. Similar results can be seen
in Type I MV regurgitation depending on the underlying
disease [10].
By contrast, in patients with a history of rheumatic
fever, because of the underlying complex valvular and
subvalvular leasions [11], conventional valve repair can
be very difficult and the durability of the repair is limited
[12]. The possibility of repair depends on the surface
area, the pliability and mobility of the anterior leaflet
(AML) and the ability of the AML to coapt against the
PML. Various complex techniques like commisurotomy,
augmentation, decalcification and chordae splitting are
used. But because of the progressive disease of the valve
and annulus, especially in young patient, the results are
rather poor. In old patients the long-term results are
better, but repair is still a challenging procedure [4]. The
MitroFixTM device may be a potential alternative to re-
store the competence of the MV with the added benefit
of preserving the EOA of the valve.
Results of standard repair in patients with ischemic
MR tend to be still worse than in degenerative disease
[13] and additional repair options, with the possibility of
restoring mitral valve function, are needed [14]. Type
IIIb MR is characterized by restricted systolic leaflet mo-
tion with preserved leaflet pliability. The basic mechan-
ism of this functional MR is tethering as a result of
segmental or global LV dilatation caused by ischemic or
non-ischemic dilated cardiomyopathy. Ischemic MRresults from restriction of the posterior leaflet motion
making it unavailable for coaptation with the anterior
leaflet. The MR is caused by changes in the geometry of
the LV and MV- apparatus in the absence of structural
damage to the valve [15]. Especially, ischemic MR is
often caused by asymmetrical tethering, resulting from
segmental dilatation following infarction or ischemic
dysfunction of the posteromedial papillary muscle. The
prevailing consequence is tethering of the PML (P2, P3,
PC) and restricted leaflet motion [13]. The surgical ap-
proach to attain competence of ischemic MR is to in-
crease or restore leaflet coaptation by myocardial
revascularization [13] to prevent further dilatation and
remodeling of the LV associated to restrictive MV annu-
loplasty. The annuloplasty is performed by downsizing 1
or 2 sizes to force the AML to coapt against the
restricted PML. But downsizing does not relieve tether-
ing – it is just shifting the posterior annulus anterior to
achieve coaptation [15].
Despite good long-term survival for patients undergo-
ing MVRP and high freedom from reoperation, many
patients with ischemic MR experience a deterioration of
the regurgitation during the first six months following
the procedure. McGee et al. [16] reported that in
patients with ischemic MR undergoing repair, the pro-
portion of those with 0 or 1+ mitral regurgitation
decreased from 71% to 41% during the first six months
following surgery, whereas the proportion of those with
3+ or 4+ regurgitation increased from 13% to 28%.
Similar recurrence rates of severe MR after primal suc-
cessful repair are reported by other authors [15,17,18].
Restrictive annuloplasty is also accompanied by the risk
of functional MV stenosis [19]. These studies suggest
that conventional repair of ischemic MR may be sub-
optimal. Hence, many surgeons still prefer MVR in
complex rheumatic, degenerative or ischemic MR, with
the view that “good replacement is better than bad re-
pair” [20]. Therefore, any innovation (device or a tech-
nique), that makes MVRP easier and feasible and also
more accessible to the majority of surgeons is very
welcome.
The intention of our study is to evaluate whether the
MitroFix™ Device leads to comparable good results in
elective cases as MVR. The design of the device was
motivated by the following key observations:
Principles for the design of the MitroFix™ device
The design of the device was motivated by the following
key observations:
1. Repair of the mitral valve is always preferable to
replacement
2. The anterior leaflet contributes 70% of the mitral
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anterior leaflet, the AML should be preserved
3. New posterior leaflet mimicking normal posterior
leaflet in closed position can simplify mitral valve
restoration while achieving EOA higher than mitral
valve replacement or repair
4. The optimal repair system should be simple making
the procedure more reliable and accessible to the
majority of surgeonsMethods
Description of the MitroFix™
The MitroFix™ consists of a ”D” shaped device with a
curved surface made of medical grade polymer covered
with pericardium (Figure 1). This shape is designed to
mimic the posterior leaflet in the closed position, form-
ing a “buttress” against which the anterior leaflet can
coapt (Figure 2). The device is available in 28, 30, 32, 34,
36 and 38 mm sizes.Figure 1 The Mitrofix™ device.Description of the MitroFix™ sizer
The Mitrofix™ sizer (Figures 3 & 4A and B) is an inte-
gral part of the Mitrofix™ repair system. The functional
sizer both enables the surgeon to accurately measure the
size of the annulus, and exactly mimics the Mitrofix™
thereby allowing the surgeon to test the function and in-
tegrity of the repair after inserting two commissural
sutures and pledgeted sutures of the posterior ring.
Proper device size selection is an important part of re-
pair using the Mitrofix™ system. A silicon tube is
attached to the luer on the atrial side of the D-shaped
sizer. Saline is injected through the luer and exits at the
ventricular side. The ventricle fills and is pressurized to
test the repair prior to implantation. This gives an im-
portant insight onto the feasibility of the repair with the
Mitrofix™ device.
From December 2006 to October 2011, 51 Mitrofix™
devices were implanted at three different centers (Augsburg/
Germany n=34, Sofia/Bulgaria n=12, Barcelona/Spain
n = 5). The patients’ characteristics are shown in
Table 1. The mean age of the patients (30 males and
21 females) was 67,72 years (range 52-85 years). Of
them, 37 were in class III or IV of the NYHA and all
patients suffered from severe MR. 31 patients had
combined surgery. Successful implantation of the
MitroFix™ device was performed in 51/53 (96,22%)
patients. The indications for the use of the Mitrofix™
device are shown in Table 2 and were: (I) severe de-
struction of the PML by endocarditis or degenerative
disease, (II) rudimentary or calcified PML, and (III)
restrictive ischemic or rheumatic PML.Surgical implantation technique
All operations were performed through a median ster-
notomy using standard cardiopulmonary bypass and
patients were monitored with TEE. After exposure of the
MV and analysis of the underlying pathology the antero-
lateral and the posteromedial trigones of the valve were
identified and one stitch in each of these areas was ap-
plied. The size of the AML was measured by using a
Carpentier Physio Ring Sizer. Then the corresponding
MitroFix-sizer was positioned at the posterior annulus
and the competence of the valve was assessed by
Figure 2 The MitroFix™ device in open (A) and coapting (B)
position with the anterior leaflet of the MV.
Figure 4 MitroFix™ sizer (view from above) placed with the
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Prolapse of the anterior leaflet did not exclude the use of
the Mitrofix™ device, but the abnormality may required
separate correction of the anterior leaflet pathology.
Thus the presence of prolapse of the anterior leaflet may
require transposition of chordae, implantation of neo-
chordae, resection or other surgical techniques.
Once the size has been chosen, mattress sutures with
pledget are threaded from the ventricular side through
the leaflet to annulus. Attaching the posterior leaflet to
the annulus preserves the subvalvular apparatus andFigure 3 Schematic view of the Mitrofix™ sizer.
anterior leaflet of the mitral valve in open (4A) and closed (4B)
position.reinforces the posterior annulus. While threading the
sutures as seen in Figure 5, there is no need to perform
an annuloplasty and undersizing (more than one size is
not recommended). The other arm of the sutures is
threaded through the middle part of the annulus of the
device. Special care was taken at both commissures, not
to compromise the commissural chordae. The MitroFix
device is then implanted like a prosthetic valve. The an-
terior bridge, which is very flexible, was cut in between
the stitches placed in the area of the trigones mimicking
an open ring; although, alternatively, the anterior bridge
of the device can be left intact and fixed to the anterior
annulus. It is worth noting that the two trigonal sutures
are important to add additional strength and stability to
the ring.
Results
Table 3 shows that the MitroFix device was successfully
implanted in 51 of the 53 operated patients (96,2%).
Table 1 Patient’s characteristics - 3 Centers - (MitroFix©
Device)
N valid












Atrial fibrillation 51 21 (41,2%)
Additional cardiac diseases 51
None 20 (39,2%)
Cardiac artery disease 18 (35,3%)
Aortic valve disease 4 (7,8%)
Tricuspid valve disease 13 (25,5%)






















(+ Endocarditis 5 (9,8%)
IIIa 14 (27,5%)
IIIb 16 (31,4%)
AML structural alteration 51
none 39 (76,5%)
Type II 7 (13,7%)
Fibrosis 5 (9,8%)
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biological valve and another one underwent a complex
mitral valve repair. The MitroFix device sizes most used
were the 32 mm and 34 mm. Almost 60% of the patients
received one or more associated cardiac surgical proced-
ure. The mean cardiopulmonary and aortic cross clamp
times are also shown in Table 3. Only one patient with
endocarditis died >30 days postoperatively of septic
shock.
As shown in Table 4, the early intraoperative and post-
operative TEE demonstrated none or only trivial residual
MR in 90,2% of the patients. In 5 patients more than
trivial MR was detected. Importantly, the mean EOA
measured by PHT was 2,51 cm2, with a peak gradient of
8,28 mmHg and a mean gradient of 4,0 mmHg during
the first postoperative control before discharge.
Three patients (5,9%) had intraoperative / postopera-
tive mitral regurgitation II or III. Patient 1 have had a re-
sidual MR II and died postoperatively due to
multiorganic failure caused by multimorbidity and thefact that he was operated in a myocardial infarction
situation.
The second patient from the Sofia-group had a re-
sidual MR II. It was an operation for a myxomatic valve,
the patient died due to multiorganic failure after replace-
ment of the MitroFix by a mechanical valve. Since then
we postulated a myxomatic valve to be a contraindica-
tion for it can cause a systolic anterior motion, SAM.
The third patient coming from the Spanish group have
had a MR III with severe endocarditic. He died 37 days
postoperatively due to multiorganic failure caused by
septic prostration.
There was no thrombosis; the anterior leaflet is still
left. The anticoagulation is comparable as after MVR:
3 month cumarine (Marcumar) aiming INR 2,5, then
there is no further anticoagulation required if the patient
shows sinus rhythm, eventually ASS 100 mg per day.
Discussion
The present study has demonstrated that severe mitral
valve regurgitation mainly due to diseased posterior leaf-
let can be repaired successfully using the MitroFix™de-
vice. The device replaces the diseased posterior leaflet
allowing the preservation of the anterior leaflet provid-
ing excellent early functional and clinical results. This is
a new concept in the surgical treatment of the mitral
valve that allows restoration of the valve competence
whilst maintaining the EOA and preserving the anterior
leaflet and the subvalvular apparatus. The importance
Figure 5 Surgical technique showing the insertion of plegeted
sutures through the posterior annulus, then passed through
the ring of the MitroFix™ and lowered into position.
Table 4 Mitral valve function after surgical correction as
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mitral valve surgery warrants further discussion
Restoration of mitral valve competence by surgical re-
pair in the presence of a severely dysfunctional or
destroyed PML can be challenging even in the hands of
cardiac surgeons highly experienced in mitral valve re-
pair surgery. Furthermore, reparative surgery of the se-
verely altered PML does not prevent the progression of
the disease and the recurrence of MR. In this context,
the use of the MitroFix™ device, which transforms the
MV into a monocuspid valve like it is done in the classic
reconstruction [8], can be a better alternative to valve re-
placement, thus avoiding the complications associated














CPB time (min) (mean/Range) 51 92,8 (47-167)
Aortic XC time (min) (mean/Range) 51 64,5 (29-118)
Failed reconstuctio/switch 53 2 (3,8%)thrombosis, degeneration). It is also likely that, in con-
trast with reconstruction of severely altered PML, the use
of the MitroFix™ would result in fewer reoccurrence of
MR and the need for redo surgery. As demonstrated in
this study, the MitroFix™ may be particularly useful in
the presence of rheumatic or ischemic MR, where owing
to the progression of the disease the middle- and long-
term results of reconstructive MV are unsatisfying
[6,15,21]. Similarly, the MitroFix™ may also be useful for
the correction of degenerative MV disease that often
requires complex valve reconstruction and which results
are less predictable [9]. Certainly, we showed that in
more than 90% of the cases a competent MV could be
restored, especially in restrictive type III MR, whereas
other investigators have reported 15-30% of residual MR
immediately after valve repair with annuloplasty [15].
The specific design and the implantation technique en-
able the surgeon to implant a rather large MitroFix™ -de-
vice without the necessity of performing a restrictive
annuloplasty, thus preserving the EOA of the MV. In the
absence of pathologies of the AML, the whole leaflet
serves as the opening surface of the valve; although in the
presence of additional changes on the AML (prolapsuis,
destruction), parts of the PML (chordae, segments) can be
used to repair the AML. In the later case there is no need
to restore the PML that can be completely replaced by the
MitroFix™ -device. The use of the MitroFix™ device also
results in a shortening of the ischemic and cardiopulmon-
ary bypass times which may be an important factor in
complex reconstructions and in the presence of reduced
cardiac function. Based on our experience, we see severe
type III alteration of the PML as the main indication for
the use of the MitroFix™, which from a technical point of
view still remains the most challenging MV pathology to
be corrected and it will represent the most frequent affect-
ation of the MV in the future [22]. The MitroFix™ may be
particularly useful in ischemic MR, where even specially
developed annuloplasty rings have not solved the problem
of recurrent MR caused by tethering [13] and extreme
downsizing resulting in substantial reduction of the EOA
[23]. Both problems can be overcome by the use of the
MitroFix™ device.
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In summary, we have demonstrated that the MitroFix™is
a device that can be used in conditions where the pos-
terior leaflet is partially or completely dysfunctional or
even destroyed by various pathologies including endo-
carditis. This is a new concept in the surgical treatment
of the mitral valve that allows restoration of the valve
competence with maintenance of the EOA and preserva-
tion of the subvalvular apparatus and the anterior leaflet.
Importantly, the device is also useful to restore compe-
tence of the ischemic mitral valve where the tethering of
the leaflets makes difficult the repair by conventional
surgical approaches.The use of the MitroFix™has the
additional advantages of shortening of the cross-clamp
time that is deemed important for the mortality and
morbidity of cardiac patients [24]and, by being an easy
and rapid learning of the technique, facilitating its use
by a larger number of surgeons with less experience in
reparative mitral valve surgery.
However, it should be clarified that in the present
study a small number of patients followed-up for a short
period of time were included and that there is a need for
a larger number of treated patients and follow-up for
longer periods of time to evaluate the value of the
device.
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